ETF Holdings Breakdown of IOVA

IOVA institutional holdings

The adjusted close for IOVA on 2025-11-12 was 2.54

The following institutional investment holdings of IOVA have been identified

Date	ETF ISIN/Name	Num Shares	Book value	Derived Price per Share	Comment
2025-11-12	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	157,304	USD 399,552 -4.3%	2.54
2025-11-12	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	20,996 -0.3%	USD 53,330 -4.7%	2.54
2025-11-12	IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc))	340,981	USD 866,092	2.54
2025-11-12	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	228,445	USD 580,250	2.54
2025-11-12	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	228,445 0.3%	USD 580,250 -4.1%	2.54
2025-11-12	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	2,185	USD 5,550 -4.3%	2.54
Total =		978,356	USD 2,485,024

Book value of shares is calculated on the adjusted close price of each day (row).

News associated with IOVA

Iovance Biotherapeutics (NASDAQ:IOVA) Shares Pass Below Two Hundred Day Moving Average – Here’s What Happened

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $2.62 and traded as low as $2.19. Iovance Biotherapeutics shares last traded at $2.22, with a volume of 9,006,027 shares trading hands. Analyst Upgrades and Downgrades A number […] - 2025-09-18 04:49:17

After Hours Most Active for Aug 21, 2025 : NVDA, AMZN, LCID, AAPL, IOVA, AVGO

The NASDAQ 100 After Hours Indicator is down -18.44 to 23,124.14. The total After hours volume is currently 97,306,839 shares traded.The following are the most active stocks for the after hours session: NVIDIA Corporation (NVDA) is -0.07 at $174.91, with 4,892,038 shares traded. - 2025-08-21 17:24:54

HC Wainwright Reiterates Buy Rating for Iovance Biotherapeutics (NASDAQ:IOVA)

Iovance Biotherapeutics (NASDAQ:IOVA – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They presently have a $20.00 price target on the biotechnology company’s stock. Other equities analysts have also recently issued research reports about the stock. Truist Financial cut […] - 2025-08-21 04:24:45

Top Stocks To Watch: IOVA Soars On Regulatory Approval, FDA Fast Tracks Aldeyra's Drug

(RTTNews) - PainReform Ltd.'s (PRFX) solar energy business unit, developing next-generation AI-driven solar analytics, DeepSolar, has been accepted into the NVIDIA Connect Program. This gives DeepSolar access to NVIDIA's AI frameworks, development tools, and engineering support t - 2025-08-19 10:36:15

Pre-Market Most Active for Aug 19, 2025 : OPEN, INTC, IOVA, TGNA, TSLL, JNJ, SQQQ, WMT, NVO, NVDA, XPEV, NIO

The NASDAQ 100 Pre-Market Indicator is down -14.36 to 23,699.4. The total Pre-Market volume is currently 178,882,121 shares traded.The following are the most active stocks for the pre-market session: Opendoor Technologies Inc (OPEN) is +0.38 at $4.16, with 20,195,663 shares trad - 2025-08-19 09:29:56

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Purchased by Chicago Partners Investment Group LLC

Chicago Partners Investment Group LLC grew its position in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 97.6% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 40,626 shares of the biotechnology company’s stock after purchasing an additional 20,067 shares […] - 2025-08-13 04:56:58

Iovance Biotherapeutics (NASDAQ:IOVA) Shares Down 5% After Analyst Downgrade

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) shares dropped 5% during mid-day trading on Monday after Wells Fargo & Company lowered their price target on the stock from $18.00 to $14.00. Wells Fargo & Company currently has an overweight rating on the stock. Iovance Biotherapeutics traded as low as $2.02 and last traded at […] - 2025-08-12 02:18:51

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Acquired by Avantax Advisory Services Inc.

Avantax Advisory Services Inc. raised its holdings in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 39.0% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 18,560 shares of the biotechnology company’s stock after acquiring an additional 5,205 shares during the […] - 2025-08-11 06:04:48

XTX Topco Ltd Takes Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

XTX Topco Ltd bought a new stake in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 181,832 shares of the biotechnology company’s stock, valued at approximately $606,000. A number of other large […] - 2025-08-06 05:20:52

TD Asset Management Inc Sells 171,200 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

TD Asset Management Inc lowered its holdings in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 55.0% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 139,878 shares of the biotechnology company’s stock after selling 171,200 shares during the period. TD Asset Management Inc’s holdings in […] - 2025-08-05 05:32:52

This Beaten-Down Healthcare Stock Could Jump 720%, According to a Wall Street Analyst. Is It Time to Buy?

Key PointsIovance launched its first product, called Amtagvi, last year. - 2025-07-29 04:29:00

Iovance Biotherapeutics Target of Unusually High Options Trading (NASDAQ:IOVA)

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) was the target of some unusual options trading on Wednesday. Traders bought 53,902 call options on the company. This is an increase of approximately 956% compared to the average volume of 5,106 call options. Institutional Trading of Iovance Biotherapeutics A number of hedge funds and other institutional […] - 2025-07-25 04:24:55

Noteworthy Wednesday Option Activity: AFRM, ADI, IOVA

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Affirm Holdings Inc (Symbol: AFRM), where a total of 29,448 contracts have traded so far, representing approximately 2.9 million underlying shares. That amounts to about - 2025-07-23 16:27:11

Iovance Biotherapeutics (NASDAQ:IOVA) Stock Rating Lowered by The Goldman Sachs Group

Iovance Biotherapeutics (NASDAQ:IOVA – Get Free Report) was downgraded by research analysts at The Goldman Sachs Group from a “neutral” rating to a “sell” rating in a research note issued on Tuesday, MarketBeat reports. A number of other research analysts have also recently weighed in on the stock. Chardan Capital cut their price objective on […] - 2025-07-17 05:14:57

Iovance Biotherapeutics (NASDAQ:IOVA) Downgraded to Sell Rating by The Goldman Sachs Group

Iovance Biotherapeutics (NASDAQ:IOVA – Get Free Report) was downgraded by The Goldman Sachs Group from a “neutral” rating to a “sell” rating in a research report issued on Tuesday, MarketBeat reports. Several other research analysts have also issued reports on IOVA. JMP Securities reiterated a “market perform” rating on shares of Iovance Biotherapeutics in a […] - 2025-07-17 05:14:57

Iovance Biotherapeutics (NASDAQ:IOVA) Rating Lowered to “Sell” at The Goldman Sachs Group

Iovance Biotherapeutics (NASDAQ:IOVA – Get Free Report) was downgraded by equities researchers at The Goldman Sachs Group from a “neutral” rating to a “sell” rating in a report issued on Tuesday, MarketBeat.com reports. Several other analysts also recently commented on IOVA. UBS Group downgraded Iovance Biotherapeutics from a “buy” rating to a “neutral” rating and […] - 2025-07-17 05:14:57

Cambridge Investment Research Advisors Inc. Buys 5,237 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

Cambridge Investment Research Advisors Inc. lifted its stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 12.9% in the 1st quarter, Holdings Channel reports. The institutional investor owned 45,877 shares of the biotechnology company’s stock after acquiring an additional 5,237 shares during the period. Cambridge Investment Research Advisors Inc.’s holdings in Iovance Biotherapeutics were […] - 2025-07-15 04:17:30

After Hours Most Active for Jun 6, 2025 : IOVA, NVDA, INTC, ACHR, AAL, CSX, AAPL, NKE, PCG, BAC, MRK, PFE

The NASDAQ 100 After Hours Indicator is up 14.86 to 21,776.65. The total After hours volume is currently 96,255,289 shares traded.The following are the most active stocks for the after hours session: Iovance Biotherapeutics, Inc. (IOVA) is +0.02 at $2.07, with 5,435,272 shares t - 2025-06-06 17:24:57

Ameriprise Financial Inc. Has $463,000 Stock Holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

Ameriprise Financial Inc. lessened its holdings in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 88.8% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 62,548 shares of the biotechnology company’s stock after selling 494,986 shares during the period. Ameriprise Financial Inc.’s holdings in Iovance Biotherapeutics […] - 2025-06-05 04:22:52

Captrust Financial Advisors Cuts Stock Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

Captrust Financial Advisors lowered its position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 42.1% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 28,738 shares of the biotechnology company’s stock after selling 20,868 shares during the period. Captrust Financial Advisors’ […] - 2025-05-23 04:47:02

Iovance Biotherapeutics (NASDAQ:IOVA) Rating Lowered to “Neutral” at UBS Group

UBS Group lowered shares of Iovance Biotherapeutics (NASDAQ:IOVA – Free Report) from a buy rating to a neutral rating in a report issued on Friday morning, Marketbeat.com reports. UBS Group currently has $2.00 price target on the biotechnology company’s stock, down from their prior price target of $17.00. Other equities research analysts also recently issued […] - 2025-05-19 02:46:52

Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 5.4% Following Analyst Downgrade

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report)’s share price fell 5.4% during mid-day trading on Tuesday after The Goldman Sachs Group lowered their price target on the stock from $16.00 to $8.00. The Goldman Sachs Group currently has a buy rating on the stock. Iovance Biotherapeutics traded as low as $1.85 and last traded […] - 2025-05-15 02:39:11

Iovance Biotherapeutics (NASDAQ:IOVA) Downgraded by Truist Financial to Hold

Truist Financial cut shares of Iovance Biotherapeutics (NASDAQ:IOVA – Free Report) from a buy rating to a hold rating in a research report sent to investors on Monday morning, MarketBeat.com reports. A number of other equities research analysts also recently weighed in on the company. Chardan Capital lowered their price target on Iovance Biotherapeutics from […] - 2025-05-13 02:56:46

Pre-Market Most Active for May 9, 2025 : TSLL, SQQQ, TQQQ, QBTS, IOVA, WOLF, NVDA, IBIT, DNB, UMC, HIMS, AEG

The NASDAQ 100 Pre-Market Indicator is up 91.45 to 20,155.02. The total Pre-Market volume is currently 99,990,466 shares traded.The following are the most active stocks for the pre-market session: Direxion Daily TSLA Bull 2X Shares (TSLL) is +0.2 at $10.57, with 10,864,676 share - 2025-05-09 09:28:55

First Trust Advisors LP Invests $2.40 Million in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

First Trust Advisors LP acquired a new position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 324,246 shares of the biotechnology company’s stock, valued at approximately $2,399,000. A number of other institutional investors also […] - 2025-05-05 05:10:51

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Stock Holdings Lessened by CANADA LIFE ASSURANCE Co

CANADA LIFE ASSURANCE Co cut its stake in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 5.7% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 57,265 shares of the biotechnology company’s stock after selling 3,484 shares during the period. CANADA LIFE ASSURANCE Co’s holdings […] - 2025-05-01 05:38:58

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Stake Raised by Invesco Ltd.

Invesco Ltd. lifted its holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 2.3% during the 4th quarter, HoldingsChannel.com reports. The firm owned 221,928 shares of the biotechnology company’s stock after acquiring an additional 4,967 shares during the quarter. Invesco Ltd.’s holdings in Iovance Biotherapeutics were worth $1,642,000 at the end of the most […] - 2025-04-30 04:46:52

After Hours Most Active for Apr 25, 2025 : NVDA, CMG, MSFT, IOVA, XOM, LNW, CMCSA, NU, TSLA, MP, PFE, NEE

The NASDAQ 100 After Hours Indicator is up 13.65 to 19,446.21. The total After hours volume is currently 107,054,554 shares traded.The following are the most active stocks for the after hours session: NVIDIA Corporation (NVDA) is -0.12 at $110.89, with 5,366,088 shares traded. A - 2025-04-25 17:29:54

Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 5.9% Following Analyst Downgrade

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report)’s stock price dropped 5.9% during trading on Tuesday after Barclays lowered their price target on the stock from $22.00 to $5.00. Barclays currently has an overweight rating on the stock. Iovance Biotherapeutics traded as low as $3.20 and last traded at $3.21. Approximately 3,959,691 shares traded hands […] - 2025-04-17 02:15:02

Geode Capital Management LLC Buys 222,425 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

Geode Capital Management LLC boosted its position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 3.9% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 5,871,420 shares of the biotechnology company’s stock after purchasing an additional 222,425 shares during the quarter. Geode Capital Management […] - 2025-04-15 05:33:09

Back to Listing

Disclaimer